Police & Firemen s Retirement System of New Jersey Has $2.62 Million Holdings in Corcept Therapeutics Incorporated $CORT

Police & Firemen s Retirement System of New Jersey grew its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 102.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 35,739 shares of the biotechnology company’s stock after buying an additional 18,074 shares during the quarter. Police & Firemen s Retirement System of New Jersey’s holdings in Corcept Therapeutics were worth $2,623,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in the company. Dimensional Fund Advisors LP raised its position in Corcept Therapeutics by 2.8% during the first quarter. Dimensional Fund Advisors LP now owns 2,136,510 shares of the biotechnology company’s stock valued at $243,708,000 after acquiring an additional 57,942 shares in the last quarter. Invesco Ltd. increased its stake in shares of Corcept Therapeutics by 76.5% during the 1st quarter. Invesco Ltd. now owns 1,246,234 shares of the biotechnology company’s stock worth $142,345,000 after purchasing an additional 540,101 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Corcept Therapeutics by 0.6% during the 1st quarter. Northern Trust Corp now owns 1,022,001 shares of the biotechnology company’s stock valued at $116,733,000 after purchasing an additional 6,486 shares in the last quarter. TD Asset Management Inc acquired a new stake in shares of Corcept Therapeutics in the 2nd quarter valued at $60,179,000. Finally, Bank of New York Mellon Corp boosted its holdings in Corcept Therapeutics by 9.5% in the second quarter. Bank of New York Mellon Corp now owns 638,722 shares of the biotechnology company’s stock worth $46,882,000 after purchasing an additional 55,629 shares in the last quarter. Institutional investors own 93.61% of the company’s stock.

Insider Buying and Selling

In other news, insider William Guyer sold 20,000 shares of the business’s stock in a transaction dated Wednesday, November 5th. The shares were sold at an average price of $75.36, for a total transaction of $1,507,200.00. Following the transaction, the insider owned 5,287 shares in the company, valued at approximately $398,428.32. The trade was a 79.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $87.54, for a total transaction of $192,588.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 259,400 shares of company stock worth $20,009,288. 20.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

CORT has been the subject of a number of analyst reports. Wall Street Zen cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, October 18th. Piper Sandler reduced their target price on Corcept Therapeutics from $131.00 to $121.00 and set an “overweight” rating for the company in a report on Friday, August 1st. Wolfe Research assumed coverage on Corcept Therapeutics in a research report on Tuesday. They set a “peer perform” rating for the company. HC Wainwright reissued a “buy” rating and issued a $145.00 price target on shares of Corcept Therapeutics in a research report on Monday, October 20th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $140.00 price objective on shares of Corcept Therapeutics in a research note on Thursday, September 25th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Corcept Therapeutics currently has an average rating of “Hold” and a consensus price target of $135.25.

Corcept Therapeutics Stock Down 0.0%

Shares of NASDAQ CORT opened at $75.11 on Wednesday. Corcept Therapeutics Incorporated has a 12 month low of $49.00 and a 12 month high of $117.33. The company has a market cap of $7.90 billion, a P/E ratio of 66.47 and a beta of 0.43. The business’s 50 day moving average is $77.63 and its two-hundred day moving average is $73.78.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.02). Corcept Therapeutics had a net margin of 18.51% and a return on equity of 20.10%. The business had revenue of $207.64 million during the quarter, compared to the consensus estimate of $223.78 million. During the same period in the prior year, the company posted $0.41 earnings per share. The firm’s revenue was up 13.8% compared to the same quarter last year. Corcept Therapeutics has set its FY 2025 guidance at EPS. Sell-side analysts expect that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

Corcept Therapeutics Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.